These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 31253167)

  • 21. Radiation therapy for extensive-stage small-cell lung cancer in the era of immunotherapy.
    Tian Y; Ma J; Jing X; Zhai X; Li Y; Guo Z; Yu J; Zhu H
    Cancer Lett; 2022 Aug; 541():215719. PubMed ID: 35597478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer.
    Wang H; Yao Z; Kang K; Zhou L; Xiu W; Sun J; Xie C; Yu M; Li Y; Zhang Y; Zheng Y; Lin G; Pan X; Wu Y; Luo R; Wang L; Tang M; Liao S; Zhu J; Zhou X; Zhang X; Xu Y; Liu Y; Peng F; Wang J; Xiang L; Yin L; Deng L; Huang M; Gong Y; Zou B; Wang H; Wu L; Yuan Z; Bi N; Fan M; Xu Y; Tong R; Yi L; Gan L; Xue J; Mo X; Chen C; Na F; Lu Y
    Med; 2024 Oct; 5(10):1237-1254.e9. PubMed ID: 38964333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-line immune-checkpoint inhibitor treatment in extensive-disease small-cell lung cancer: A classical and network meta-analysis.
    Mutlu H; Bozcuk H; Artaç M; Eser İ
    J Cancer Res Ther; 2023 Apr; 19(Supplement):S6-S11. PubMed ID: 37147977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opportunities and obstacles of targeted therapy and immunotherapy in small cell lung cancer.
    Yu L; Lai Q; Gou L; Feng J; Yang J
    J Drug Target; 2021 Jan; 29(1):1-11. PubMed ID: 32700566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new hope: the immunotherapy in small cell lung cancer.
    Li Q; Yuan D; Ma C; Liu Y; Ma L; Lv T; Song Y
    Neoplasma; 2016; 63(3):342-50. PubMed ID: 26925794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
    Wang C; Li J; Zhang Q; Wu J; Xiao Y; Song L; Gong H; Li Y
    BMC Cancer; 2021 Aug; 21(1):968. PubMed ID: 34454455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers.
    Chang YL; Yang CY; Huang YL; Wu CT; Yang PC
    Oncotarget; 2017 Mar; 8(11):18021-18030. PubMed ID: 28152514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
    Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
    BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical Development of Immunotherapy for Small Cell Lung Cancer].
    Yu T; Zhong D
    Zhongguo Fei Ai Za Zhi; 2018 Dec; 21(12):918-923. PubMed ID: 30591100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy in Advanced Non-Small Cell Lung Cancer.
    Huang J; Reckamp KL
    Semin Respir Crit Care Med; 2020 Jun; 41(3):400-408. PubMed ID: 32450594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival.
    Zhang CY; Sun H; Su JW; Chen YQ; Zhang SL; Zheng MY; Li YF; Huang J; Zhang C; Tai ZX; Cai M; Zhang XC; Su J; Xu CR; Yan HH; Chen HJ; Wu YL; Yang JJ
    Lung Cancer; 2023 Jan; 175():68-78. PubMed ID: 36473332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tackling the current dilemma of immunotherapy in extensive-stage small cell lung cancer: A promising strategy of combining with radiotherapy.
    Kang K; Wu Y; Yao Z; Lu Y
    Cancer Lett; 2023 Jul; 565():216239. PubMed ID: 37211066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of first-line anti-PD-L1 blockades combined with brain radiotherapy for extensive-stage small-cell lung cancer with brain metastasis.
    Ma J; Tian Y; Hao S; Zheng L; Hu W; Zhai X; Meng D; Zhu H
    J Neurooncol; 2022 Sep; 159(3):685-693. PubMed ID: 35976547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer.
    Cooper MR; Alrajhi AM; Durand CR
    Am J Ther; 2018; 25(3):e349-e356. PubMed ID: 29722737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC.
    Taniguchi H; Caeser R; Chavan SS; Zhan YA; Chow A; Manoj P; Uddin F; Kitai H; Qu R; Hayatt O; Shah NS; Quintanal Villalonga Á; Allaj V; Nguyen EM; Chan J; Michel AO; Mukae H; de Stanchina E; Rudin CM; Sen T
    Cell Rep; 2022 May; 39(7):110814. PubMed ID: 35584676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges.
    Meng X; Liu Y; Zhang J; Teng F; Xing L; Yu J
    Cancer Lett; 2017 Oct; 405():29-37. PubMed ID: 28688973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immune Characteristics of Small Cell Lung Cancer].
    Zhu Y; Wu S
    Zhongguo Fei Ai Za Zhi; 2020 Oct; 23(10):889-896. PubMed ID: 33070515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Facts and Hopes on Cancer Immunotherapy for Small Cell Lung Cancer.
    Zugazagoitia J; Osma H; Baena J; Ucero AC; Paz-Ares L
    Clin Cancer Res; 2024 Jul; 30(14):2872-2883. PubMed ID: 38630789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.